Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

  1. Bardia, A.
  2. Cortés, J.
  3. Bidard, F.-C.
  4. Neven, P.
  5. Garcia-Sáenz, J.
  6. Aftimos, P.
  7. O'Shaughnessy, J.
  8. Lu, J.
  9. Tonini, G.
  10. Scartoni, S.
  11. Paoli, A.
  12. Binaschi, M.
  13. Wasserman, T.
  14. Kaklamani, V.
Aldizkaria:
Clinical cancer research : an official journal of the American Association for Cancer Research

ISSN: 1557-3265

Argitalpen urtea: 2024

Alea: 30

Zenbakia: 19

Orrialdeak: 4299-4309

Mota: Artikulua

DOI: 10.1158/1078-0432.CCR-24-1073 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus